Shravani Shitole on Muck Rack

Shravani Shitole

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Shravani

Contact Shravani, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial

|
By Zev A. Wainberg, Gulam A. Manji, Nathan Bahary, Susanna V Ulahannan, Shubham Pant, David R. Spigel, Nataliya V. Uboha, Paul E. Oberstein, Anwaar Saeed, Ji Kim, Ning WANG, Ben Weeder, Karim Mrouj, Jennifer Scott, Daniel DiRenzo, Matthew Walters, Wilson Wu, Soonweng Cho, Eileen M. O’Reilly, Brandon Beagle, Shravani Shitole, Lisa G. Ensign, Angelo Kaplan, Omar Kabbarah
| Nature Verified
Abstract Quemliclustat potently inhibits CD73, a key enzyme producing immunosuppressive adenosine. In a phase 1b trial (ARC-8), we evaluated safety and efficacy of quemliclustat combined with gemcitabine/nab-paclitaxel (G/nP) with or without zimberelimab (anti-programmed cell death protein 1 (PD-1)) in first-line metastatic pancreatic ductal adenocarcinoma (PDAC).
Open in Who Shared Issue with article?
See all 1 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified